Fasiglifam 25 mg BID vs 50 mg QD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.
Epistemonikos ID: 50feb51325f735ec531ab43fd03750aabc7732b5
First added on: May 11, 2024